Contact
pdf downloadPSV validated Data Poster Download                            pdf downloadProtocol Download 

To meet accumulated mutating of SARS-CoV-2, GeneMedi keeps continually developing novel solutions and tools for efficacy evaluation of COVID-19 vaccines (and neutralized antibodies) against novel mutant SARS-CoV-2 (2019nCoV) lineages. Our scientist's team takes duty in fighting against the COVID-19 pandemic with our global industrial and academic partners.

1. GeneMedi information and products collection of SARS-COV-2 (2019nCOV) UK B.1.1.7 lineage and South Africa 501Y.V2 lineage and Brazilian P.1 lineage(B.1.1.28.1)

Background Reading:
Information and products collection of SARS-COV-2 (2019nCOV) UK B.1.1.7 lineage
Information and products collection of SARS-COV-2 (2019nCOV) South Africa 501Y.V2 lineage
information and products collection of SARS-COV-2 (2019nCOV) Brazilian P.1 lineage (B.1.1.28.1)

GeneMedi pseudotyped virus (pseudovirus) of SARS-COV-2 (2019nCOV) B.1.1.7 lineage

GeneMedi pseudotyped virus (pseudovirus) of SARS-COV-2 (2019nCOV) 501Y.V2 lineage

GeneMedi pseudotype virus (pseudovirus) of SARS-COV-2 (2019nCOV) P.1 lineage(B.1.1.28.1, Brazilian variant)

SARS-COV-2 (2019nCOV) B.1.1.7 lineage & 501Y.V2 lineage(B.1.351) & P.1 lineage (B.1.1.28.1, Brazilian variant) of Spike protein & ACE2 competition binding assay for efficacy evaluation of COVID-19 vaccines and therapeutic antibodies

GeneMedi codon-optimized spike mammalian expression vector for SARS-COV-2 (2019nCOV) B.1.1.7 lineage

GeneMedi codon-optimized spike mammalian expression vector for SARS-COV-2 (2019nCOV) South Africa 501Y.V2 lineage(B.1.351).

GeneMedi codon-optimized spike mammalian expression vector for SARS-COV-2 (2019nCOV) - P.1 lineage(B.1.1.28.1, Brazilian variant)

2. Multiple variants of Spike protein & ACE2 competition binding assay for efficacy evaluation of COVID-19 vaccines and therapeutic antibodies



The Spike proteins variants that GeneMedi offer is including:

1) Multiple variants of recombinant Spike protein for Spike protein & ACE2 competition binding assay for efficacy evaluation of COVID-19 vaccines and therapeutic antibodies

2) Recombinant human ACE2 protein products

Cat No. Antigen Name of 2019-nCoV(SARS-CoV-2) Isotypes Order
GMP-H-ACE2001Recombinant human solubale ACE2 protein
(soluble hACE2, extracellular hACE2, C-His)
Mammalian (human cell)Picture loading failed.
GMP-H-ACE2002Recombinant human solubale ACE2 protein
(soluble hACE2, extracellular hACE2, C-His)
Mammalian (human cell)Picture loading failed.

- Competition assay for neutralizing antibodies, peptides inhibitor and vaccines-immunized serums
Picture loading failed.

Figure. Immobilized 2019-nCoV S Protein RBD-C-His (GMP-V-2019nCoV-SRBD001) can bind 10μg/ml of Human ACE-2-Fc (GMP-H-ACE2002)



3. Multi-VariantsTM SARS-CoV2 (wildtype, D614G, N501Y, E484K, B.1.1.7 lineage, 501Y.V2 lineage, and so on) Pseudotype virus-Based Neutralization Assay System for efficacy evaluation of COVID-19 vaccines and therapeutic antibodies (Lentiviral pseudovirus)

Protocol: GeneMedi SARS-CoV2 pseudovirus-based neutralization assay-protocol        pdf downloadProtocol Download

4. Codon-optimized mammalian expression vector for SARS-COV-2 (2019nCOV) spike wide type & mutant variants (D614G, N501Y, E484K, B.1.1.7 lineage, 501Y.V2 lineage, and so on)

Cat No. Gene &Vector description of 2019 nCoV Vector Order
GMV-V-2019nCoV-017 pGM-2019nCoV-spike protein (S protein,S1+S2) pcDNA3.1(+) Picture loading failed.
GMV-V-2019nCoV-008 pGM-2019nCoV-spike protein (S protein,S1+S2) pcDNA3.1(+) Picture loading failed.
GMV-V-2019nCoV-054 pGM-2019nCoV-spike D614G protein (S protein,S1+S2,D614G) pcDNA3.1(+) Picture loading failed.
GMV-V-2019nCoV-057 pGM-2019nCoV-spike S943P protein (S protein,S1+S2,S943P) pcDNA3.1(+) Picture loading failed.
GMV-V-2019nCoV-058 pGM-2019nCoV-spike V367F protein (S protein,S1+S2,V367F) pcDNA3.1(+) Picture loading failed.
GMV-V-2019nCoV-059 pGM-2019nCoV-spike G476S protein (S protein,S1+S2,G476S) pcDNA3.1(+) Picture loading failed.
GMV-V-2019nCoV-060 pGM-2019nCoV-spike V483A protein (S protein,S1+S2,V483A) pcDNA3.1(+) Picture loading failed.
GMV-V-2019nCoV-061 pGM-2019nCoV-spike H49Y protein (S protein,S1+S2,H49Y) pcDNA3.1(+) Picture loading failed.
GMV-V-2019nCoV-062 pGM-2019nCoV-spike Q239K protein (S protein,S1+S2,Q239K) pcDNA3.1(+) Picture loading failed.
GMV-V-2019nCoV-063 pGM-2019nCoV-spike A831V protein (S protein,S1+S2,A831V) pcDNA3.1(+) Picture loading failed.
GMV-V-2019nCoV-064 pGM-2019nCoV-spike P1263L protein (S protein,S1+S2,P1263L) pcDNA3.1(+) Picture loading failed.
GMV-V-2019nCoV-065 pGM-2019nCoV-spike D839Y/N/E-D839Y protein (S protein,S1+S2,D839Y/N/E-D839Y) pcDNA3.1(+) Picture loading failed.
GMV-V-2019nCoV-066 pGM-2019nCoV-spike D839Y/N/E-D839N protein (S protein,S1+S2,D839Y/N/E-D839N ) pcDNA3.1(+) Picture loading failed.
GMV-V-2019nCoV-067 pGM-2019nCoV-spike D839Y/N/E-D839E protein (S protein,S1+S2,D839Y/N/E-D839E) pcDNA3.1(+) Picture loading failed.
GMV-V-2019nCoV-099 pGM-2019nCoV-Spike trimer ( P2-mutant,S1/S2 cleavage site(furin cleavage sequence)-mutant,trimerization modified) pcDNA3.1(+) Picture loading failed.
GMV-V-2019nCoV-100 pGM-Spike of SARS-COV-2 B.1.1.7 lineage whole mutation pcDNA3.1(+) Picture loading failed.
GMV-V-2019nCoV-101 pGM-2019nCoV-Spike(S1+S2)-RBD N501Y mutation(B.1.1.7 lineage RBD) pcDNA3.1(+) Picture loading failed.
GMV-V-2019nCoV-102 pGM-2019nCoV-Spike(S1+S2)-S1 HV 69-70 Deletion mutation(ΔH69/ΔV70,B.1.1.7 lineage) pcDNA3.1(+) Picture loading failed.
GMV-V-2019nCoV-107 pGM-2019nCoV-Spike(S1+S2)-E484K mutation(501Y.V2 lineage) pcDNA3.1(+) Picture loading failed.
GMV-V-2019nCoV-109 pGM-Spike(S1+S2)RBD triple mutation of 501Y.V2 lineage(K417N, E484K and N501Y) pcDNA3.1(+) Picture loading failed.
GMV-V-2019nCoV-111 pGM-Spike (S1+S2) whole mutation variant of SARS-CoV-2(2019nCoV) 501Y.V2 lineage pcDNA3.1(+) Picture loading failed.


Codon-optimized viral particle (Adenovirus, Lentivirus, AAV) for SARS-COV-2 (2019nCOV) spike wide type & mutant variants (D614G, N501Y, E484K, B.1.1.7 lineage, 501Y.V2 lineage, and so on)

Cat No. Gene &Vector description of 2019 nCoV Vector Reporter Order
GMV-V-2019nCoV-051 pGMLV-2019nCoV-spike(S1+S2,C-6His) Lentiviral vector Zsgreen Picture loading failed.
GMV-V-2019nCoV-001 pGMLV-2019nCoV-spike(S1+S2,C-6His) Lentiviral vector Zsgreen Picture loading failed.
GMV-V-2019nCoV-053 Ad-2019nCoV-Spike(S1+S2,C-3FLAG) Pre-made adenovirus null Picture loading failed.
GMV-V-2019nCoV-047 Ad-2019nCoV-Spike(S1+S2,C-3FLAG) Pre-made adenovirus EGFP Picture loading failed.
GMV-V-2019nCoV-002 pGMLV-2019nCoV-S1(C-6His) Lentiviral vector Zsgreen Picture loading failed.
GMV-V-2019nCoV-048 Ad-2019nCoV-Spike(S1 protein,C-3FLAG) Pre-made adenovirus EGFP Picture loading failed.
GMV-V-2019nCoV-003 pGMLV-2019nCoV-Spike RBD(C-6His) Lentiviral vector Zsgreen Picture loading failed.
GMV-V-2019nCoV-007 pGMAAV-2019nCoV-Spike RBD(C-3FLAG) AAV vector Zsgreen Picture loading failed.
GMV-V-2019nCoV-050 AAV-2019nCoV-Spike(S protein RBD,C-3FLAG) Pre-made AAV Zsgreen Picture loading failed.
GMV-V-2019nCoV-049 Ad-2019nCoV-Spike(S protein RBD,C-3FLAG) Pre-made adenovirus EGFP Picture loading failed.
GMV-V-2019nCoV-056 Ad-2019nCoV-Spike D614G (S protein,S1+S2,D614G) Pre-made adenovirus null Picture loading failed.
GMV-V-2019nCoV-103 pGM-2019nCoV-Spike trimer ( P2-mutant,S1/S2 cleavage site(furin cleavage sequence)-mutant,trimerization modified) Pre-made adenovirus null Picture loading failed.
GMV-V-2019nCoV-104 pGM-Spike of SARS-COV-2 B.1.1.7 lineage whole mutation Pre-made adenovirus null Picture loading failed.
GMV-V-2019nCoV-105 Ad-2019nCoV-Spike(S1+S2)-RBD N501Y mutation(B.1.1.7 lineage RBD) Pre-made adenovirus null Picture loading failed.
GMV-V-2019nCoV-106 Ad-2019nCoV-Spike(S1+S2)-S1 HV 69-70 Deletion mutation(ΔH69/ΔV70,B.1.1.7 lineage) Pre-made adenovirus null Picture loading failed.
GMV-V-2019nCoV-108 Ad-2019nCoV-Spike(S1+S2)-E484K mutation(501Y.V2 lineage) Pre-made adenovirus null Picture loading failed.
GMV-V-2019nCoV-110 Ad-Spike(S1+S2)RBD triple mutation of 501Y.V2 lineage(K417N, E484K and N501Y) Pre-made adenovirus null Picture loading failed.
GMV-V-2019nCoV-112 Ad-Spike (S1+S2) whole mutation variant of SARS-CoV-2(2019nCoV) 501Y.V2 lineage Pre-made adenovirus null Picture loading failed.


5. 293T-ACE2 stable cell line & human ACE2 expression vectors: Effector cell of pseudotype virus-Based Neutralization Assay System for efficacy evaluation of COVID-19 vaccines and therapeutic antibodies (Lentiviral pseudovirus)

Human ACE2 overexpression stable HEK293T cell lines. Catalot Number: GM-SC-293T-hACE2-01 Click here for details

Product list: Human ACE2 expression vectors
Cat No. 2019 nCoV
related Gene
Gene &Vector description of 2019 nCoV Vector Reporter Tag codon
Optimized
Order
GMV-V-2019nCoV-045 TMPRSS2 pGMLv-hTMPRSS2(C-3FLAG) Lentiviral vector Zsgreen C-3FLAG No Picture loading failed.
GMV-V-2019nCoV-041 ACE2 pGMLV-hACE2(C-3FLAG) Lentiviral vector Zsgreen C-3FLAG No Picture loading failed.
GMV-V-2019nCoV-042 ACE2 pAD-hACE2(C-3FLAG) Pre-made Adenovirus EGFP C-3FLAG No Picture loading failed.
GMV-V-2019nCoV-046 TMPRSS2 pGMLv-mtmprss2(C-3FLAG) Lentiviral vector Zsgreen C-3FLAG No Picture loading failed.
GMV-V-2019nCoV-043 ACE2 pAD-mACE2(C-3FLAG) Pre-made Adenovirus EGFP C-3FLAG No Picture loading failed.
GMV-V-2019nCoV-044 ACE2 pGMLV-mACE2(C-3FLAG) Lentiviral vector Zsgreen C-3FLAG No Picture loading failed.

Validation of hACE2 overexpression stable HEK293T cell lines (Cat. GM-SC-293T‐hACE2-01)
Picture loading failed. Picture loading failed.

Figure. ACE2 mRNA level Validation in hACE2 overexpression stable HEK293T cell lines: Cat. GM‐SC‐293T‐hACE2‐01 (A) and the cell lines were tested as Mycoplasma free (B).

Products list: Human ACE2 overexpression stable HEK293T cell lines
Cat No. 2019 nCoV
related Gene
Gene &Vector description of 2019 nCoV Vector Reporter Tag codon
Optimized
Order
GMV-V-2019nCoV-041 ACE2 pGMLV-hACE2(C-3FLAG) Lentiviral vector Zsgreen C-3FLAG No Picture loading failed.
GMV-V-2019nCoV-042 ACE2 pAD-hACE2(C-3FLAG) Pre-made Adenovirus EGFP C-3FLAG No Picture loading failed.
GMV-V-2019nCoV-043 ACE2 pAD-mACE2(C-3FLAG) Pre-made Adenovirus EGFP C-3FLAG No Picture loading failed.
GMV-V-2019nCoV-044 ACE2 pGMLV-mACE2(C-3FLAG) Lentiviral vector Zsgreen C-3FLAG No Picture loading failed.


6. Validated SARS-CoV-2 neutralizing antibodies-benchmark COVID-19 neutralizing antibodies.

Cat No. Antigen Name of 2019-nCoV(SARS-CoV-2) Source
(Expression Host)
Isotypes Bioactivity validation Order
GMP-V-2019nCoV-SnAb001Anti-2019-nCoV Spike (Spike RBD domain) human monoclonal neutralizing antibody (IgG1)Mammalian (human cell)human IgG1Validated in COVID-19 Spike protein and Spike-RBD protein binding affnity.
COVID-19 related neutralizing potency is validated by
1.2019nCoV pseudotyped virus based neutralization assay in 293T-ACE2 effector cell.
2. competitively blocking the binding of ACE-2 receptor with SARS-CoV-2 Spike protein.
Picture loading failed.
GMP-V-2019nCoV-SnAb002Anti-2019-nCoV Spike (Spike RBD domain) human monoclonal neutralizing antibody (IgM)Mammalian (human cell)human IgMValidated in COVID-19 Spike protein and Spike-RBD protein binding affnity.
COVID-19 related neutralizing potency is validated by
1.2019nCoV pseudotyped virus based neutralization assay in 293T-ACE2 effector cell.
2. competitively blocking the binding of ACE-2 receptor with SARS-CoV-2 Spike protein.
Picture loading failed.
GMP-V-2019nCoV-SnAb003Anti-2019-nCoV Spike (Spike RBD domain) human monoclonal neutralizing antibody (IgA)Mammalian (human cell)human IgAValidated in COVID-19 Spike protein and Spike-RBD protein binding affnity.
COVID-19 related neutralizing potency is validated by
1.2019nCoV pseudotyped virus based neutralization assay in 293T-ACE2 effector cell.
2. competitively blocking the binding of ACE-2 receptor with SARS-CoV-2 Spike protein.
Picture loading failed.
GMP-V-2019nCoV-SnAb004Anti-2019-nCoV Spike (Spike RBD domain) mouse monoclonal neutralizing antibody (IgG1)Mammalian (human cell)mouse IgG1Validated in COVID-19 Spike protein and Spike-RBD protein binding affnity.
COVID-19 related neutralizing potency is validated by
1.2019nCoV pseudotyped virus based neutralization assay in 293T-ACE2 effector cell.
2. competitively blocking the binding of ACE-2 receptor with SARS-CoV-2 Spike protein.
Picture loading failed.
GMP-V-2019nCoV-SnAb005Anti-2019-nCoV Spike (Spike RBD domain) Cynomolgus monoclonal neutralizing antibody (IgG1)Mammalian (human cell)Cynomolgus (Non human primate, NHP) IgG1Validated in COVID-19 Spike protein and Spike-RBD protein binding affnity.
COVID-19 related neutralizing potency is validated by
1.2019nCoV pseudotyped virus based neutralization assay in 293T-ACE2 effector cell.
2. competitively blocking the binding of ACE-2 receptor with SARS-CoV-2 Spike protein.
Picture loading failed.


GeneMedi-SARS-CoV-2 WT and Spike Mutation Variants Pseudovirus (PSV) Based Neutralizing 
Assay with GeneMedi's anti-2019-nCoV Spike Neutralizing antibodies (Nabs)
Picture loading failed.Picture loading failed.

Figure. The Pseudovirus (PSV) Based Neutralizing Assay was performed on 293T-hACE2 cells infected with GeneMedi-SARS-CoV-2 WT and Spike Mutation Variants (D614G, S943P, V367F, G476S, V483A, H49Y, Q239K, A831V, P1263L, D839Y/N/E:D839Y, D839N, D839E) Pseudovirus (PSV) under treatment of GeneMedi's anti-2019-nCoV Spike Neutralizing antibodies (Nabs) . Inhibition rate was determined by comparing the relative RFP+GFP+/GFP+ rate.

GeneMedi's anti-2019-nCoV Spike Neutralizing antibodies (Nabs) and Spike RBD protein binding validation
Picture loading failed. Picture loading failed. Picture loading failed. Picture loading failed. Picture loading failed.
Cat No. Product EC50 (ng/ml)
GMP-V-2019nCoV-SnAb001 Anti-2019-nCoV Spike (Spike RBD domain) human monoclonal neutralizing antibody (IgG1) 5
GMP-V-2019nCoV-SnAb002 Anti-2019-nCoV Spike (Spike RBD domain) human monoclonal neutralizing antibody (IgM) 18
GMP-V-2019nCoV-SnAb003 Anti-2019-nCoV Spike (Spike RBD domain) human monoclonal neutralizing antibody (IgA) 410
GMP-V-2019nCoV-SnAb004 Anti-2019-nCoV Spike (Spike RBD domain) mouse monoclonal neutralizing antibody (IgG1) 6.8
GMP-V-2019nCoV-SnAb005 Anti-2019-nCoV Spike (Spike RBD domain) Cynomolgus monoclonal neutralizing antibody (IgG1) 28

Figure. The binding of GeneMedi's anti-2019-nCoV Spike Neutralizing antibodies (Nabs) to Recombinant 2019-nCoV(SARS-CoV-2) Spike RBD protein (GMP-V-2019nCoV-SRBD001) at 5.0ug/ml (100uL/well) was measured by ELISA.

A.GMP-V-2019nCoV-SnAb001:Anti-2019-nCoV Spike (Spike RBD domain) human monoclonal neutralizing antibody (IgG1)
B.GMP-V-2019nCoV-SnAb002:Anti-2019-nCoV Spike (Spike RBD domain) human monoclonal neutralizing antibody (IgM)
C.GMP-V-2019nCoV-SnAb003:Anti-2019-nCoV Spike (Spike RBD domain) human monoclonal neutralizing antibody (IgA)
D.GMP-V-2019nCoV-SnAb004:Anti-2019-nCoV Spike (Spike RBD domain) mouse monoclonal neutralizing antibody (IgG1)
E.GMP-V-2019nCoV-SnAb005:Anti-2019-nCoV Spike (Spike RBD domain) Cynomolgus monoclonal neutralizing antibody (IgG1)

GeneMedi's anti-2019-nCoV Spike Neutralizing antibodies (Nabs) competitive binding assay validation
Picture loading failed. Picture loading failed. Picture loading failed. Picture loading failed. Picture loading failed.
Cat No. Product IC50 (ng/ml)
GMP-V-2019nCoV-SnAb001 Anti-2019-nCoV Spike (Spike RBD domain) human monoclonal neutralizing antibody (IgG1) 26.3
GMP-V-2019nCoV-SnAb002 Anti-2019-nCoV Spike (Spike RBD domain) human monoclonal neutralizing antibody (IgM) 84.2
GMP-V-2019nCoV-SnAb003 Anti-2019-nCoV Spike (Spike RBD domain) human monoclonal neutralizing antibody (IgA) 20.5
GMP-V-2019nCoV-SnAb004 Anti-2019-nCoV Spike (Spike RBD domain) mouse monoclonal neutralizing antibody (IgG1) 81.9
GMP-V-2019nCoV-SnAb005 Anti-2019-nCoV Spike (Spike RBD domain) Cynomolgus monoclonal neutralizing antibody (IgG1) 243

Figure. GeneMedi's anti-2019-nCoV Spike Neutralizing antibodies (Nabs) block Recombinant 2019-nCoV(SARS-CoV-2) Spike RBD protein (GMP-V-2019nCoV-SRBD001) and hACE2 (GMP-H-ACE2002) binding.

A.GMP-V-2019nCoV-SnAb001:Anti-2019-nCoV Spike (Spike RBD domain) human monoclonal neutralizing antibody (IgG1)
B.GMP-V-2019nCoV-SnAb002:Anti-2019-nCoV Spike (Spike RBD domain) human monoclonal neutralizing antibody (IgM)
C.GMP-V-2019nCoV-SnAb003:Anti-2019-nCoV Spike (Spike RBD domain) human monoclonal neutralizing antibody (IgA)
D.GMP-V-2019nCoV-SnAb004:Anti-2019-nCoV Spike (Spike RBD domain) mouse monoclonal neutralizing antibody (IgG1)
E.GMP-V-2019nCoV-SnAb005:Anti-2019-nCoV Spike (Spike RBD domain) Cynomolgus monoclonal neutralizing antibody (IgG1)

GeneMedi's efficacy evaluation solutions will be useful for your anti-COVID-19 candidates funtional assay and evaluation,which is including:
1) Types of Vaccines (by testing immunized serum from human, mouse, NHP etc.)
2) Neutralizing antibodies
3) Peptides blockers (peptide inhibitors)
4) Compounds targeting Spike induced cell-fusion.



References

1. 2 Korber, B. et al. Spike mutation pipeline reveals the emergence of a more transmissible form of SARS-CoV-2. bioRxiv Preprint., doi:10.1101/2020.04.29.069054 (2020). 2. Investigation of novel SARS-COV-2 variant. Public health England. 3. European Centre for Disease Prevention and Control. Rapid increase of a SARS-CoV-2 variant with multiple spike protein mutations observed in the United Kingdom – 20 December 2020.ECDC: Stockholm; 2020. 4. Li, G. & De Clercq, E. Therapeutic options for the 2019 novel coronavirus (2019-nCoV). Nature Reviews Drug Discovery, doi:10.1038/d41573-020-00016-0 (2020). 5. Haque, A. & Pant, A. B. Efforts at COVID-19 Vaccine Development: Challenges and Successes. Vaccines 8, doi:10.3390/vaccines8040739 (2020). 6. Dong, Y. et al. A systematic review of SARS-CoV-2 vaccine candidates. Signal Transduction and Targeted Therapy 5, doi:10.1038/s41392-020-00352-y (2020). 7. Andrew Rambaut1, N. L., Oliver Pybus, Wendy Barclay, Jeff Barrett5, Alesandro Carabelli6, Tom Connor, Tom Peacock, David L Robertson8, Erik Volz, . Preliminary genomic characterisation of an emergent SARS-CoV-2 lineage in the UK defined by a novel set of spike mutations. https://virological.org/ (2020). 8. Rapid increase of a SARS-CoV-2 variant with multiple spike protein mutations observed in the United Kingdom. European Centre for Disease Prevention and Control: Publications & data. 9. Zhang, L. et al. SARS-CoV-2 RNA reverse-transcribed and integrated into the human genome. bioRxiv Preprint. , doi:10.1101/2020.12.12.422516 (2020).




GENEMEDI
6th Floor, Buiding No.2, Kangxin Road 3377, Shanghai, China
Email: [email protected] [email protected]
Telephone: +86-21-50478399   Fax: 86-21-50478399
Privacy Policy
Chinese Website

Apply for
Free
Sample

Sample FOC application

×